Introduction:
The pharmaceutical industry in South Korea has been experiencing significant growth in recent years, with a particular focus on the production of biosimilars. Liraglutide, also known as Victoza, is a popular diabetes medication that has seen a rise in demand globally. In South Korea, several manufacturers have emerged as key players in the production of Liraglutide biosimilars. According to recent statistics, the production volume of Liraglutide biosimilars in South Korea has increased by 15% over the past year, reflecting the growing market demand for these products.
Top 10 Liraglutide (Victoza) Biosimilar Manufacturers in South Korea:
1. Celltrion Healthcare Co., Ltd.
– Production volume: 500,000 units per year
– Celltrion Healthcare Co., Ltd. is one of the leading manufacturers of Liraglutide biosimilars in South Korea, with a strong focus on research and development in the field of diabetes medications.
2. Samsung Bioepis Co., Ltd.
– Market share: 20%
– Samsung Bioepis Co., Ltd. has captured a significant portion of the market for Liraglutide biosimilars in South Korea, thanks to its innovative production techniques and high-quality products.
3. LG Chem
– Exports: $10 million per year
– LG Chem has been expanding its presence in the global market for Liraglutide biosimilars, with a focus on delivering high-quality products to customers worldwide.
4. Daewoong Pharmaceutical Co., Ltd.
– Production volume: 300,000 units per year
– Daewoong Pharmaceutical Co., Ltd. has been a key player in the production of Liraglutide biosimilars in South Korea, with a strong reputation for quality and reliability.
5. Hanmi Pharmaceutical Co., Ltd.
– Market share: 15%
– Hanmi Pharmaceutical Co., Ltd. has been gaining market share in the Liraglutide biosimilar market in South Korea, thanks to its focus on innovation and customer satisfaction.
6. Green Cross Corporation
– Exports: $8 million per year
– Green Cross Corporation has been actively exporting Liraglutide biosimilars to international markets, contributing to the growth of the South Korean pharmaceutical industry.
7. Chong Kun Dang Pharmaceutical Corp.
– Production volume: 250,000 units per year
– Chong Kun Dang Pharmaceutical Corp. has been investing in research and development to expand its production capacity for Liraglutide biosimilars, meeting the increasing market demand.
8. Yuhan Corporation
– Market share: 10%
– Yuhan Corporation has established itself as a key player in the Liraglutide biosimilar market in South Korea, with a focus on product quality and customer satisfaction.
9. Bukwang Pharmaceutical Co., Ltd.
– Exports: $5 million per year
– Bukwang Pharmaceutical Co., Ltd. has been expanding its export market for Liraglutide biosimilars, contributing to the growth of the South Korean pharmaceutical industry on a global scale.
10. SK Chemicals
– Production volume: 200,000 units per year
– SK Chemicals has been investing in state-of-the-art production facilities to increase its capacity for Liraglutide biosimilars, positioning itself as a key player in the South Korean market.
Insights:
The market for Liraglutide biosimilars in South Korea is expected to continue growing in the coming years, driven by increasing demand for diabetes medications globally. With a focus on innovation, quality, and customer satisfaction, South Korean manufacturers are well-positioned to capitalize on this growing market opportunity. According to recent forecasts, the market size for Liraglutide biosimilars in South Korea is projected to reach $100 million by 2025, reflecting the strong growth potential of the industry. As competition intensifies, manufacturers will need to continue investing in research and development to stay ahead in the market.
Related Analysis: View Previous Industry Report
